- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.04. | BioAegis and Prenosis partner for inflammatory disease therapies | ||
| 22.04. | Health Canada approves Biocon's two denosumab biosimilars | ||
| 21.04. | Eli Lilly doubles down on in vivo with $7bn Kelonia buyout | ||
| 21.04. | Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy | ||
| 21.04. | Asahi Kasei acquires German company Aicuris | ||
| 20.04. | British patients risking "fake" weight loss drugs, despite safety concerns, survey says | ||
| 20.04. | Boehringer Ingelheim launches AI centre in London | ||
| 20.04. | Trump backs psychedelics for mental health in new executive order | ||
| 20.04. | UCB to purchase Neurona and NRTX-1001 for $1.15bn | ||
| 20.04. | MSD secures EC approval for Enflonsia to prevent infant RSV infection | ||
| 17.04. | Kailera makes history with record-breaking $625m IPO | ||
| 17.04. | Aligos and Xiamen Amoytop sign deal for HBV therapy | ||
| 17.04. | Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions | ||
| 16.04. | Developers back Alzheimer's drugs despite report suggesting lack of efficacy | ||
| 16.04. | Lilly debuts more Foundayo data as FDA requests post-marketing trials | ||
| 16.04. | Terremoto wins $108m in Series C to drive cancer and rare disease programmes | ||
| 16.04. | Nucleai and Sirona Dx to provide new proteomics solution for pharma companies | ||
| 16.04. | Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study | ||
| 15.04. | FDA shares guide on genome editing best practices | ||
| 15.04. | Amazon launches AI drug discovery platform | ||
| 15.04. | J&J sets the tone for Q1 earnings with strong oncology growth | ||
| 15.04. | Adcendo secures $75m in Series C funding for ADC development | ||
| 15.04. | Lilly to acquire CrossBridge Bio for up to $300m | ||
| 14.04. | EU sees 2025 pharma export uptick amid competitiveness concerns | ||
| 14.04. | Pharma 5.0, Sustainability & Security: PHARMAP 2026 brings pharma's future into focus |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.